Helix BioPharma Corp. (TSE:HBP – Get Rating) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.20 and traded as high as C$0.26. Helix BioPharma shares last traded at C$0.26, with a volume of 26,174 shares traded.
Helix BioPharma Price Performance
The company has a quick ratio of 0.67, a current ratio of 0.69 and a debt-to-equity ratio of 2.60. The stock has a market capitalization of C$44.46 million and a price-to-earnings ratio of -4.55. The company’s 50-day simple moving average is C$0.20 and its 200 day simple moving average is C$0.21.
Helix BioPharma (TSE:HBP – Get Rating) last released its quarterly earnings results on Tuesday, June 14th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. Equities research analysts forecast that Helix BioPharma Corp. will post -0.11 EPS for the current year.
Helix BioPharma Company Profile
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada.
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.